Literature DB >> 12495471

Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells.

Joe Matsumoto1, Masako Kaneda, Mitsuhiro Tada, Jun-ichi Hamada, Shunichi Okushiba, Satoshi Kondo, Hiroyuki Katoh, Tetsuya Moriuchi.   

Abstract

Activated Akt/protein kinase B transmits oncogenic signals leading to inhibition of apoptosis, cellular proliferation, and tolerance to hypoxia. Presently, mutational inactivation of PTEN and activation of Ras are considered to be the major causes of Akt activation. Here we report differential mechanisms of constitutive Akt activation in 4 human pancreatic cancer cell lines (KMP-3, KMP-4, PCI-66, and PCI-68). These 4 cell lines displayed phosphorylation and functional activation of Akt both in the presence and absence of serum, while three control cell lines (PCI-79, KMP-8, and PSN-1) did so only in the presence of serum in culture. All the 7 cell lines harbored K-Ras activated by mutations at codon 12 resulting in MAP kinase kinase (MEK1/2) phosphorylation, and all except one (KMP-8) had p53 mutations, indicating that these mutations are not sufficient for constitutive Akt activation. KMP-3 and KMP-4 had lost PTEN function owing to loss of expression or a mutation, but PCI-66 and PCI-68 retained wild-type PTEN. Phosphorylation of Akt was inhibited by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and the tyrosine kinase inhibitor genistein in KMP-3 and KMP-4 cells, indicating that upstream signals are required for Akt activation in these two cell lines. In contrast, neither LY294002 nor genistein inhibited Akt activation in PCI-66 and PCI-68 cells, indicating the involvement of another unknown mechanism of Akt activation independent of PI3K-mediated signaling to Akt. Irrespective of the differential mechanisms, the 4 cell lines showed similar mRNA expression patterns of 49 genes assessed by cDNA array as compared to the 3 cell lines without Akt activation, suggesting that the mechanisms have the same consequences on the downstream signaling of the constitutive Akt activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495471      PMCID: PMC5926936          DOI: 10.1111/j.1349-7006.2002.tb01240.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  61 in total

1.  Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3.

Authors:  Y Ohba; N Mochizuki; S Yamashita; A M Chan; J W Schrader; S Hattori; K Nagashima; M Matsuda
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

2.  Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis.

Authors:  J Q Cheng; D A Altomare; M A Klein; W C Lee; G D Kruh; N A Lissy; J R Testa
Journal:  Oncogene       Date:  1997-06-12       Impact factor: 9.867

3.  High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay.

Authors:  H Kashiwazaki; H Tonoki; M Tada; I Chiba; M Shindoh; Y Totsuka; R Iggo; T Moriuchi
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

4.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors:  P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1.

Authors:  M J Wick; L Q Dong; R A Riojas; F J Ramos; F Liu
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

6.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

7.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

Authors:  D Haas-Kogan; N Shalev; M Wong; G Mills; G Yount; D Stokoe
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

8.  Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF).

Authors:  H Kamohara; K Sakamoto; T Ishiko; S Mita; Y Masuda; T Abe; M Ogawa
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1994-08

9.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.

Authors:  R Gum; E Lengyel; J Juarez; J H Chen; H Sato; M Seiki; D Boyd
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

View more
  8 in total

1.  A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.

Authors:  Junan Li; Jiuxiang Zhu; W Scott Melvin; Tanios S Bekaii-Saab; Ching-Shih Chen; Peter Muscarella
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

2.  Ack1 tyrosine kinase activation correlates with pancreatic cancer progression.

Authors:  Kiran Mahajan; Domenico Coppola; Y Ann Chen; Weiwei Zhu; Harshani R Lawrence; Nicholas J Lawrence; Nupam P Mahajan
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

3.  Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.

Authors:  Kiran Mahajan; Domenico Coppola; Sridevi Challa; Bin Fang; Y Ann Chen; Weiwei Zhu; Alexis S Lopez; John Koomen; Robert W Engelman; Charlene Rivera; Rebecca S Muraoka-Cook; Jin Q Cheng; Ernst Schönbrunn; Said M Sebti; H Shelton Earp; Nupam P Mahajan
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

4.  ARK5 is a tumor invasion-associated factor downstream of Akt signaling.

Authors:  Atsushi Suzuki; Jie Lu; Gen-Ichi Kusakai; Atsuhiro Kishimoto; Tsutomu Ogura; Hiroyasu Esumi
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

Review 5.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

6.  RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer.

Authors:  Kathryn Leake; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 7.  ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.

Authors:  K Mahajan; N P Mahajan
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

8.  Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.

Authors:  M G Schlieman; B N Fahy; R Ramsamooj; L Beckett; R J Bold
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.